Fresenius Medical Care Analyst Ratings
Fresenius Medical Care Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/24/2023 | — | HSBC | Upgrades | Reduce → Hold | |
| 10/11/2023 | 21.58% | Truist Securities | $28 → $24 | Maintains | Hold |
| 07/13/2023 | 41.84% | Truist Securities | $26 → $28 | Maintains | Hold |
| 05/10/2023 | 31.71% | Truist Securities | $24 → $26 | Maintains | Hold |
| 04/13/2023 | 21.58% | Truist Securities | $22 → $24 | Maintains | Hold |
| 02/23/2023 | 11.45% | Truist Securities | $17 → $22 | Maintains | Hold |
| 06/22/2022 | 36.78% | Truist Securities | $34 → $27 | Maintains | Hold |
| 11/23/2021 | — | HSBC | Initiates Coverage On | → Hold | |
| 11/17/2021 | 77.3% | RBC Capital | $42 → $35 | Maintains | Sector Perform |
| 11/11/2021 | — | Jefferies | Upgrades | Underperform → Hold | |
| 05/21/2020 | 143.16% | SunTrust Robinson Humphrey | $46 → $48 | Maintains | Buy |
| 05/11/2020 | 133.03% | SunTrust Robinson Humphrey | $42 → $46 | Maintains | Buy |
| 04/13/2020 | 112.77% | SunTrust Robinson Humphrey | $46 → $42 | Maintains | Buy |
| 02/21/2020 | 133.03% | CFRA | $38 → $46 | Upgrades | Hold → Buy |
| 01/21/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 10/23/2019 | — | Redburn Partners | Downgrades | Buy → Neutral | |
| 08/01/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/20/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/24/2023 | — | 匯豐銀行 | 升級 | 減少 → 按住 | |
| 2023 年 11 月 10 日 | 21.58% | Truist 證券 | 28 美元 → 24 美元 | 維護 | 保持 |
| 07/13/2023 | 41.84% | Truist 證券 | 26 美元 → 28 美元 | 維護 | 保持 |
| 05/10/2023 | 31.71% | Truist 證券 | 24 美元 → 26 美元 | 維護 | 保持 |
| 04/13/2023 | 21.58% | Truist 證券 | 22 美元 → 24 美元 | 維護 | 保持 |
| 02/23/2023 | 11.45% | Truist 證券 | 17 美元 → 22 美元 | 維護 | 保持 |
| 06/22/2022 | 36.78% | Truist 證券 | 34 美元 → 27 美元 | 維護 | 保持 |
| 11/23/2021 | — | 匯豐銀行 | 啓動覆蓋範圍開啓 | → 按住 | |
| 11/17/2021 | 77.3% | 加拿大皇家銀行資本 | 42 美元 → 35 美元 | 維護 | 行業表現 |
| 11/11/2021 | — | 傑富瑞集團 | 升級 | 表現不佳 → 持有 | |
| 05/21/2020 | 143.16% | SunTrust 羅賓遜·漢弗萊 | 46 美元 → 48 美元 | 維護 | 買 |
| 05/11/2020 | 133.03% | SunTrust 羅賓遜·漢弗萊 | 42 美元 → 46 美元 | 維護 | 買 |
| 2020 年 4 月 13 日 | 112.77% | SunTrust 羅賓遜·漢弗萊 | 46 美元 → 42 美元 | 維護 | 買 |
| 02/21/2020 | 133.03% | CFRA | 38 美元 → 46 美元 | 升級 | 持有 → 買入 |
| 2020 年 1 月 21 日 | — | 傑富瑞集團 | 升級 | 持有 → 買入 | |
| 2019 年 10 月 23 日 | — | Redburn 合作伙伴 | 降級 | 買入 → 中性 | |
| 08/01/2019 | — | BTIG | 降級 | 買入 → 中性 | |
| 06/20/2019 | — | 巴克萊 | 升級 | 重量相等 → 超重 |
What is the target price for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的目標價格是多少？
The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by HSBC on November 24, 2023. The analyst firm set a price target for $0.00 expecting FMS to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
匯豐銀行於2023年11月24日公佈了費森尤斯醫療（紐約證券交易所代碼：FMS）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計FMS將在12個月內跌至12個月內（可能下跌-100.00％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的最新分析師評級是多少？
The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by HSBC, and Fresenius Medical Care upgraded their hold rating.
匯豐銀行提供了費森尤斯醫療保健（紐約證券交易所代碼：FMS）的最新分析師評級，費森尤斯醫療上調了持有評級。
When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?
費森尤斯醫療（FMS）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on November 24, 2023 so you should expect the next rating to be made available sometime around November 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與費森尤斯醫療公司的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。費森尤斯醫療的最新評級是在2023年11月24日發佈的，因此您應該預計下一個評級將在2024年11月24日左右公佈。
Is the Analyst Rating Fresenius Medical Care (FMS) correct?
分析師對費森尤斯醫療（FMS）的評級是否正確？
While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Fresenius Medical Care (FMS) is trading at is $19.74, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的費森尤斯醫療保健（FMS）評級已上調，目標股價爲0.00美元至0.00美元。費森尤斯醫療保健（FMS）目前的交易價格爲19.74美元，超出了分析師的預期區間。